Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company’s imaging agent, A9-3202, which entered the clinic last year Robert Meehan, M.D., appointed as Chief… Read More
This milestone is a key step toward public reimbursement; decisions now rest with provincial and territorial governments to ensure patients can benefit from this important treatment. MISSISSAUGA, ON – GSK… Read More
FRANKLIN LAKES, NJ BD (Becton, Dickinson and Company), a leading global medical technology company, and ChemoGLO™, a specialist in hazardous drug detection and decontamination, announced a strategic collaboration to advance… Read More
Quebec has the highest rate of breast cancer in Canada.1 The Government of Quebec recently endorsed lowering the breast cancer screening age for women,2,3 reflecting the province’s commitment to earlier diagnosis and… Read More
BIOTECanada welcomes the launch of CanReview, a pan-Canadian initiative supported by the Accelerating Clinical Trials (ACT) Consortium, as a major step forward for Canada’s life sciences ecosystem. By replacing multiple… Read More
